Table 1.

Baseline characteristics of all patients

Variable	Characteristics	Number	%
Gender	Men	393	60
	Women	265	40
Age (years)	< 50	437	66
	≥ 50	221	34
BMI (kg/m2)	< 18.5	80	12
	18.5 to 25.0	430	65
	≥ 25.0	148	23
Pathological types	Fibrosarcoma	151	23
	Liposarcoma	91	14
	Undifferentiated pleomorphic sarcoma	149	23
	Leiomyosarcoma	27	4
	Synovial sarcoma	77	12
	Rhabdomyosarcoma	38	6
	Alveolar soft part sarcoma	12	2
	Epithelioid sarcoma	15	2
	Angiosarcoma	13	2
	Malignant peripheral nerve sheath tumor	38	6
	Mesenchymal chondrosarcoma	20	3
	Others	27	4
Tumor size	< 5 cm	322	49
	≥ 5 cm	336	51
Tumor site	Upper extremity	82	13
	Lower extremity	216	33
	Thoracic/trunk/abdominal wall	191	29
	Intra-abdominal	71	11
	Head/neck	80	12
	Others*	18	3
Tumor depth	Superficial	235	36
	Deep	423	64
Tumor grade	G1	130	20
	G2	304	46
	G3	201	31
	GX	23	4
AJCC stage	IA	88	13
	IB	45	7
	II	233	35
	IIIA	132	20
	IIIB	75	11
	IV	12	2
	Unknown	73	11
NLR	< 2.51	453	69
	≥ 2.51	205	31
PLR	< 164.5	516	78
	≥ 164.5	142	22
HS-mGPS	0	311	62
	1-2	194	38
CONUT	0	227	35
	1	208	32
	2-12	223	34
Albumin score	0	606	92
	2/4/6	52	8
Total lymphocyte score	0	327	50
	1	253	38
	2/3	78	12
Total cholesterol score	0	477	73
	1	118	18
	2/3	63	10
Endpoint	Alive	484	74
	Dead	174	26
Recurrence	Yes	250	38
	No	408	62
Metastasis	Yes	94	14
	No	564	86
Adjuvant therapy	None	467	71
	Chemotherapy	41	6
	Radiotherapy	44	7
	Combined chemoradiotherapy	11	2
	Unknown	95	14

^*Including the perineum, crissum, pleural cavity, and pulmonary system

HS-mGPS = high-sensitivity modified Glasgow prognostic score